Myxomavirus-derived serpin prolongs survival and reduces inflammation and hemorrhage in an unrelated lethal mouse viral infection by Virgin, Herbert W & et al,




Myxomavirus-derived serpin prolongs survival and
reduces inflammation and hemorrhage in an
unrelated lethal mouse viral infection
Herbert W. Virgin
Washington University School of Medicine in St. Louis
et al
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Virgin, Herbert W. and et al, ,"Myxomavirus-derived serpin prolongs survival and reduces inflammation and hemorrhage in an
unrelated lethal mouse viral infection." Antimicrobial Agents and Chemotherapy.57,9. 4114. (2013).
http://digitalcommons.wustl.edu/open_access_pubs/2331
  Published Ahead of Print 17 June 2013. 
10.1128/AAC.02594-12. 
2013, 57(9):4114. DOI:Antimicrob. Agents Chemother. 
Virgin and Alexandra Lucas
Thoburn, David A. Lomas, Francis G. Spinale, Herbert W.
Tibbetts, Colin Macaulay, Grant McFadden, Robert 
Heinz Feldmann, James Strong, Katrina R. Grau, Scott
Bartee, Maureen Long, Jennifer Davids, Jennifer Williams, 
Hao Chen, Donghang Zheng, Jeff Abbott, Liying Liu, Mee Y.
 
Viral Infection
Hemorrhage in an Unrelated Lethal Mouse
Survival and Reduces Inflammation and 
Myxomavirus-Derived Serpin Prolongs
http://aac.asm.org/content/57/9/4114






This article cites 39 articles, 15 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 




arch 8, 2014 by W










arch 8, 2014 by W







Myxomavirus-Derived Serpin Prolongs Survival and Reduces
Inflammation and Hemorrhage in an Unrelated Lethal Mouse Viral
Infection
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Lethal viral infections produce widespread inflammation with vascular leak, clotting, and bleeding (disseminated intravascular
coagulation [DIC]), organ failure, and highmortality. Serine proteases in clot-forming (thrombotic) and clot-dissolving (throm-
bolytic) cascades are activated by an inflammatory cytokine storm and also can induce systemic inflammation with loss of nor-
mal serine protease inhibitor (serpin) regulation. Myxomavirus secretes a potent anti-inflammatory serpin, Serp-1, that inhibits
clotting factor X (fX) and thrombolytic tissue- and urokinase-type plasminogen activators (tPA and uPA) with anti-inflamma-
tory activity in multiple animal models. Purified serpin significantly improved survival in a murine gammaherpesvirus 68
(MHV68) infection in gamma interferon receptor (IFN-R) knockout mice, a model for lethal inflammatory vasculitis. Treat-
ment of MHV68-infected mice with neuroserpin, a mammalian serpin that inhibits only tPA and uPA, was ineffective. Serp-1
reduced virus load, lung hemorrhage, and aortic, lung, and colon inflammation inMHV68-infected mice and also reduced virus
load. Neuroserpin suppressed a wide range of immune spleen cell responses after MHV68 infection, while Serp-1 selectively in-
creased CD11c splenocytes (macrophage and dendritic cells) and reduced CD11b tissue macrophages. Serp-1 altered gene
expression for coagulation and inflammatory responses, whereas neuroserpin did not. Serp-1 treatment was assessed in a second
viral infection, mouse-adapted Zaire ebolavirus in wild-type BALB/c mice, with improved survival and reduced tissue necrosis.
In summary, treatment with this unique myxomavirus-derived serpin suppresses systemic serine protease and innate immune
responses caused by unrelated lethal viral infections (both RNA and DNA viruses), providing a potential new therapeutic ap-
proach for treatment of lethal viral sepsis.
In severe viral infections and sepsis, as for bacterial sepsis, there ishigh associated mortality, up to 40 to 70%, in viral infections
where treatment is very limited (1–8). Once a patient is in shock,
treatment options are often restricted to hemodynamic support.
In septic states, widespread intravascular clotting and hemorrhage
called disseminated intravascular coagulation (DIC) can occur,
leading to microvascular thrombosis, organ damage, and shock
(1–8). The excessive clot formation depletes coagulation factors,
which, in turn, can cause excess bleeding (consumptive coagu-
lopathy). Activation of thrombotic and thrombolytic proteases
and also inflammatory responses is reciprocal (1–9). With dys-
regulated coagulation, there is massive upregulation of cytokines
and other inflammatory mediators. This cytokine storm contrib-
utes to tissue damage, producing leaky capillaries (permeable
blood vessels) and increasing virulence with, in some cases, dys-
functional immune responses (1–3).
Treatments for lethal sepsis and associated DIC that target
thrombotic and thrombolytic pathways have been reported and
include clot inhibitors, such as anti-thrombin III (9), activated
protein C (10), tissue factor pathway inhibitor (TFPI), and throm-
bomodulin, as well as agents that block hemorrhage, such as factor
VII (fVIII) (11). These approaches have produced only moderate
(6 to 19%) reductions in death rates (5–11). Anti-inflammatory
approaches, such as interleukin 10 (IL-10), for treatment of sepsis
have also been tested, again with variable success in clinical trials
(1–8). Additionally, low levels of protease activation, as in cancer
and infection, can influence innate immune responses without
overt coagulopathic or hemorrhagic changes. A combined thera-
peutic approach targeting both thrombotic and thrombolytic
pathways, as well as associated excess inflammation, may be nec-
essary to improve outcomes in severe septic states.
Large DNA viruses provide a new source of multifunctional
immunomodulating proteins used as defenses that protect the
virus against host attacks (12–14). Many such viral immuno-
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modulators have evolved over millions of years to become highly
potent and often point to central pathways that represent pivotal
regulatory points in the immune response system and thus excel-
lent targets for new therapeutic approaches. Myxomavirus se-
cretes a serpin, Serp-1, that inhibits both thrombolytic and throm-
botic proteases, as well as displaying marked anti-inflammatory
activity in a wide range of animal models. Serp-1 inhibits tissue-
and urokinase-type plasminogen activators (tPA and uPA) and
plasmin in the clot-dissolving (thrombolytic) cascade and also
factor X (fX) (13–15) in the clot-forming (thrombotic) cascade.
Serp-1 also inhibits thrombin (factor II [fII]) in the presence of
heparin, a glycosaminoglycan, but is cleaved by thrombin in the
absence of heparin (15). Purified Serp-1 protein has proven anti-
inflammatory activity in animal models of vascular injury after
balloon angioplasty and stent implantation (12, 14, 16–18) and
transplantation (18–21) and also in arthritis (22). In contrast, the
mammalian serpin, neuroserpin (NSP), inhibits only tPA and
uPA and not fII or fX (23), but it can reduce plaque growth and
stroke volume in arterial injury models (21). Serp-1 has been suc-
cessfully tested in a recent phase IIa trial for treatment of acute
coronary syndromes with stent implant (24), with a statistically
significant drop in two biomarkers of cardiovascular damage, in-
dicating reduced ischemic injury that is in part caused by micro-
embolization (24, 25). Serp-1 also produced a trend toward re-
duced D-dimer, a marker for dysfunctional coagulation (DIC)
(14).
We examined the capacity of Serp-1 to improve outcome in
two mouse models of lethal viral sepsis: gammaherpesvirus 68
(MHV68) infection in gamma interferon receptor (IFN-R)
knockout mice (26, 27) and mouse-adapted Zaire ebolavirus in-
fections in BALB/c wild-type mice. MHV68 serves as a recognized
model for human inflammatory vasculitis and lethal herpesvirus
infections. To assess for the capacity to alter the course of a second
unrelated hemorrhagic lethal virus infection in wild-type mice,
Serp-1 treatment of mouse-adapted Zaire ebolavirus, a category A
virus (28, 29), in BALB/c mice was also examined. MHV causes
high mortality in IFN-R knockout mice but not in wild-type
mice. Ebolavirus is a filovirus that induces the bleeding diathesis
seen in viral hemorrhagic fevers (VHF) and disables the immune
response. Both infections result in more than 80% mortality in the
mouse models, although the mouse-adapted Zaire ebolavirus
does not induce the pulmonary hemorrhage seen in humans,
while the MHV68-infected model does display severe pulmonary
hemorrhage. Serp-1 and mammalian serpin, NSP, treatment were
compared in MHV68-infected mice to differentiate effects of in-
hibition of thrombotic and thrombolytic proteases in infected
mice.
MATERIALS AND METHODS
Ethics statement. All animal studies conform to local and national guide-
lines for animal care and experimentation. All procedures were approved
by the University of Florida IACUC and by the Canadian Science Centre
for Human and Animal Health (CSCHAH) Animal Care Committee,
NML, PHAC (Winnipeg, Manitoba, Canada).
MHV68 passage and preparation. MHV68 was provided by the lab-
oratory of H. Virgin (26, 27). Viral MHV68 stocks were generated in 3T12
cells (ATCC, Manassas, VA). 3T12 cells were cultured in medium consist-
ing of Dulbecco modified Eagle medium (DMEM), 10% fetal calf serum
(FCS), 10 mM HEPES, 2 mM L-glutamine, and 1% penicillin or strepto-
mycin. At 50% confluence, cells were infected at a multiplicity of infection
(MOI) of 0.1. Seven days postinfection, cells underwent freeze-thaw and
the lysate was transferred to Nalgene Oak Ridge polypropylene copolymer
(PPCO) tubes and centrifuged (15 min at 4,300 g). Cleared supernatant
was centrifuged for 2 h at 12,000 g. The pellet was rinsed with phosphate-
buffered saline (PBS), resuspended in medium, vortexed, and stored at
80°C in 250-l aliquots. Virus titers were determined in duplicate.
Ebolavirus source.The 1976 Mayinga isolate of ebolavirus from Zaire
(now the Democratic Republic of the Congo) (4, 28, 29) was isolated from
a human specimen on Vero E6 cells and passaged twice prior to initiation
of these experiments. Focus-forming units (FFU) for Zaire ebolavirus
were assayed by Ebola virus matrix protein (VP40)-specific antiserum.
Protein expression and purification. Serp-1 protein was kindly pro-
vided by Viron Therapeutics Inc. (London, Ontario, Canada). Serp-1 was
purified from supernatant of recombinant Chinese hamster ovary (CHO)
cells by sequential column chromatographic separation as described pre-
viously (14–20, 23). Serp-1 protein was 354 amino acids, with a purity
greater than 99% monomer as determined by overloaded colloidal blue
gels (see Fig. S1 in the supplemental material) and reverse-phase high-
performance liquid chromatography (HPLC). Purified Serp-1 protein has
94.5% potency for uPA inhibition activity assayed by chromogenic assay
as previously described.
NSP protein was expressed in BL21(DE3) pLysS cells (Invitrogen,
Carlsbad, CA) (21). Medium containing LB, ampicillin (Amp), and chlor-
amphenicol (Cap) was inoculated with cells and grown to an optical den-
sity (OD) of 0.5 at 600 nm and 37°C at 250 rpm. Cells were cooled to 16°C
and induced with 1 mM IPTG (isopropyl -D-1-thiogalactopyranoside)
and pelleted. Cell pellets were resuspended in lysis buffer (20 mM Tris, 20
mM imidazole, 150 mM NaCl) containing EDTA-free complete protease
inhibitors (Roche) and 2 mM 4-(2-aminoethyl) benzenesulfonyl fluoride
hydrochloride (AEBSF). Samples were French pressed, and the cell debris
was pelleted at 15,000 rpm. Supernatant was loaded onto equilibrated
cobalt-nitrilotriacetic acid (NTA) (Sigma-Aldrich, St. Louis, MO),
washed with 100 volumes of lysis buffer, and eluted with elution buffer (20
mM Tris, 150 mM imidazole, 150 mM NaCl). NSP was dialyzed into 0.9%
saline and concentrated using a 10-kDa-cutoff Amicon Ultra (Millipore)
and then passed through a 0.22-m filter (Millipore). A single band was
also detected for NSP by gel electrophoresis and inhibitory activity mea-
sured for uPA or tPA by chromogenic assay (data not shown; Assaypro, St.
Louis, MO) (14, 15, 17–21, 24).
Experimental animal protocols. Pure IFN-R knockout (IFN-
R/) mice (B6.129S7-Ifngr1tm1Agt/J) and wild-type mice (BALB/c), 5 to
7 weeks of age, were purchased from JaxLabs (Sacramento, CA) and bred
under specific-pathogen-free conditions. Littermate controls were used
for all studies.
MHV68 infection. Ninety (6 to 10 mice per group) IFN-R/ mice
were infected by intraperitoneal (i.p.) injection of 12.5 106 PFU or 6
106 PFU of MHV68 given in 0.1 ml of DMEM (26). Mice were treated with
either saline control (100l), Serp-1 (100g/kg of body weight/100l) or
NSP (100 g/kg/100 l) given at the time of infection and then daily by
i.p. injection for a total of 10 days starting on the day of MHV68 infection.
Serp-1 treatment was also tested with 10 days of treatment starting 21 days
postinfection (n 12) or with 30 days of treatment starting on the day of
infection (n  10) or starting 7 days postinfection (n  12). Mice were
monitored up for 10 days and 5, 12, and 15 weeks. Mice were carefully
monitored by the veterinary animal care staff to minimize potential suf-
fering. Euthanasia was performed as previously described (14–21).
In vitroMHV68 replication assay.NIH 3T12 murine fibroblasts were
infected in vitro with wild-type MHV68 at an MOI of 0.05 in the absence
or presence of 500 ng/ml of Serp-1. At 96 h postinfection, cells and super-
natant fluid were harvested, and viral titers were determined by plaque
assay. Plaque assays were performed on NIH 3T12 cells. Briefly, 10-fold
serial dilutions of samples were prepared in serum-free DMEM, and then
infections were performed in 400 l at 37°C for 1 h. Cells were then
overlaid with a 1:1 mixture of methylcellulose (Sigma) and MEM supple-
mented with 10% fetal calf serum and antibiotics. At 7 days postinfection,
plaques were visualized by neutral red staining and counted.
Viral Serpin Improves Survival in Lethal Infections
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Ebolavirus infection. Wild type BALB/c mice were infected i.p. with a
mouse-adapted Zaire ebolavirus 1976 Mayinga strain (10 the 60% lethal
dose [LD60]). Immediately prior to infection, mice were treated with ei-
ther saline or Serp-1 at 5-, 50-, or 100-g/kg doses given by intravenous
(i.v.) tail vein bolus. Subsequent daily i.p. injections of control saline or
Serp-1 were given for a total of 10 daily doses or until euthanasia. The
usual survival time is 6 to 7 days after ebolavirus infection, and based upon
this, treated mice that survived past this point were monitored for a total
of 14 days and then euthanized whether ill or healthy. Mice were main-
tained in the biosafety level 4 (BSL4) facility in Winnipeg, Manitoba,
Canada (J. Strong and H. Feldmann). Tissues were harvested and frozen
for histopathological analysis. In a second series of mouse infections, mice
were euthanized at 6 days after ebolavirus infection and tissues taken for
pathological and quantitative reverse transcription-PCR (qRT-PCR) ge-
nome analysis (FFU equivalent) examination as follows. RNA was isolated
from these tissue samples by homogenization in 0.25% trypsin-EDTA
with subsequent extraction using a QIAampViralRNA minikit (Qiagen).
ZEBOV-GP (Zaire ebolavirus glycoprotein) was detected using the Light-
Cycler 480 RNA Master hydrolysis probe (Roche Diagnostics) and the
following: forward primer, 5=-GGCCAACGAGACGACTCAA-3=; reverse
primer, 5=-AAAGGTGCGTAGCTCAGTTGTG-3=; and probe, 6-carboxy-
fluorescein (FAM)-CTCTTCAACTGTTCCTGAGAG-MGBNFQ. All
samples were run on a Smart Cycler (ABI Biosystems) through quantita-
tive RT-PCR. All samples were quantified by being run against known
serially diluted samples extracted and run as described above. The limit of
sensitivity of the ZEBOV GP-specific quantitative RT-PCR is0.1 FFU/
ml.
Histological and morphometric analysis. At follow up, mice were
euthanized and organ tissue harvested as well as blood samples. All spec-
imens from HV68-infected mice, with or without serpin treatment,
were cut into 2 equal lengths (aorta, 3 to 5 mm, and other organs, 0.5 cm)
and then cut into halves, one for histology and one for mRNA and protein
analysis. Sections from ebolavirus-infected mouse tissues were fixed in
BSL4 facility following approved standard operating protocols and then
used for histology. For histology, sections were fixed in neutral buffered
formalin (NBF), embedded in paraffin, and cut into 4-m-thick cross
sections and stained with hematoxylin and eosin (H&E), as described
previously (14–21). Cellular invasion and tissue hemorrhage and necrosis
were measured using an Olympus DP71 camera attached to an BX51
microscope (Olympus America Inc., Center Valley, PA) and quantified
using Image Pro 6.0 (MediaCybernetics Inc., Bethesda, MD) (14–21).
Cytokine assays. Blood samples (1 ml) were obtained fromHV68-
infected mice at the time of sacrifice, placed in chilled EDTA tubes, and
centrifuged, and plasma was stored at80°C. At the time of assay, plasma
samples were subjected to multiplex array for cytokines (human MAP
base kit LUH000; R&D Systems, Minneapolis, MN) and measured simul-
taneously, minimizing interassay variability. Multiplex array was vali-
dated using internal controls for each cytokine (30). Levels of IL-1, IL-2,
IL-4, IL-6, tumor necrosis factor alpha (TNF-	), IFN-, and granulocyte-
macrophage colony-stimulating factor (GM-CSF) in plasma were mea-
sured. Plasma samples (20 l) were undiluted. The relative fluorescence
for each cytokine (Bio-Plex 200; Bio-Rad Laboratories, Hercules, CA) was
converted to an absolute concentration using calibration curves generated
from known recombinant standards. The average sensitivity for cytokines
was 0.3 pg/ml. The coefficient of variation for these assays was 15% or less.
IL-10 was additionally measured in plasma samples using an enzyme-
linked immunosorbent assay (ELISA) kit (31–33).
IHC. Immunohistochemical (IHC) staining of invading cells was per-
formed using a rabbit-specific horseradish peroxidase (HRP)/diamino-
benzidine (DAB) detection IHC kit (ab64261; Abcam, Cambridge, MA)
per the manufacturer’s protocol (14–21). Tissue sections were stained as
previously described with primary antibodies (anti-MHV68 polyclonal
rabbit serum and preimmune rabbit serum provided by H. Virgin [26,
27], 1:500 for MHV68 detection, 1:100 for CD3
 T cells, and 1:400 for
CD11b
 macrophages) with secondary rabbit-specific HRP-conjugated
antibody for MHV68, CD3, and CD11b staining. Sections were counter-
stained with hematoxylin. Positively stained cells were counted in three
high-power-field (HPF) areas in each tissue section. No staining was ob-
served in infected tissues incubated with preimmune serum or in unin-
fected tissues incubated with immune serum.
Flow cytometry. Splenocytes isolated from one mouse were not pres-
ent in high enough counts for flow cytometry analysis; therefore, spleen
cells from the same experimental group were pooled and stained with
antibodies to surface or intracellular antigens and incubated for 30 min at
room temperature (21). Labeled cells were washed and resuspended with
150l of PBS and assessed by flow cytometry. For staining of intracellular
antigens, cell pellets in 500l were incubated with fixation-permeabiliza-
tion buffer (eBioscience, San Diego, CA), incubated in the dark for 45
min, treated with permeabilization buffer (eBioscience), and incubated
with intracellular antibody mix, with further incubation for 30 min at 4°C.
All antibodies were purchased from eBiosciences and Biolegend (San Di-
ego, CA) (see Table S4 in the supplemental material). Table S1 in the
supplemental material lists immune cell types analyzed and correspond-
ing fluorochrome-labeled antibodies. Flow cytometry was performed
with a CyAn ADP Analyzer (Dako, Fort Collins, CO) (14, 21, 32). Data
were analyzed using Gatelogic software (eBioscience).
RT-PCR analysis of aortic specimens.MHV68-infected mouse aortic
sections were collected in RNA Later (Ambion, Austin, TX), and RNA was
isolated using an RNeasy minikit by following the manufacturer’s proto-
col (Qiagen, Valencia, CA). RNA was reverse transcribed to cDNA using a
Superscript VILO cDNA synthesis kit (no. 11754-250; Invitrogen Corpo-
ration, CA), and real-time PCR was carried out using a SYBR green core
reagent kit and a model 7300 RT-PCR system (Applied Biosystems, Aus-
tin, TX) (14, 20, 21, 32). Primers are listed in Table S2 in the supplemental
material.
Bleeding time assays. For the bleeding assay, mice were anesthetized
with ketamine and xylazine (80 mg/kg and 5 mg/kg), the tail was pre-
warmed for 5 min in 10 ml of saline at 37°C in a water bath, and a 3-mm
tail segment was amputated and immediately returned to the saline.
Bleeding time was measured as the time between the start of bleeding to
cessation of bleeding.
Statistical analysis. Statistical analysis was performed using Statview,
version 5.01 (SAS, Inc., Cary, NC) (14–21). Survival was assessed by Ka-
plan-Meier analysis. Only mice requiring early euthanasia prior to the
designated follow-up time were included in survival analyses. Mean cell
counts or areas of tissue hemorrhage or necrosis were calculated from
three sections for each specimen isolated from each mouse. Mean values
were used for subsequent statistical analyses. Multiple-group compari-
sons were performed using analysis of variance (ANOVA) with Fisher’s
protected least significant difference (PLSD) and unpaired two-tailed Stu-
dent’s t test for subgroup analysis (12–21, 23). A P value of 0.05 is
considered significant.
RESULTS
Serp-1 prolongs survival in herpesvirus (MHV68)-infected
mice. In an initial study, Serp-1 treatment was given by daily in-
traperitoneal (100 g/kg) injections for the first 10 days postin-
fection (6 106 to 12.5 106 PFU) starting on the day of MHV68
infection. With 10 days of treatment, Serp-1 significantly pro-
longed survival in gamma interferon receptor-deficient mice
(B6.129S7-Ifngr1tm1Agt/J, IFN-R/) (P  0.048; Fig. 1A). Sa-
line-treated HV68-infected mice survived for up to 42 days,
whereas Serp-1-treated mice survived for up to 55 days (n  60
mice, 6 to 12 mice/group) (Table 1). Early improved survival with
Serp-1 treatment was lost by 12 weeks postinfection. NSP treat-
ment (100 g/kg i.p. for 10 days) (Table 1) in a separate series of
HV68-infected IFN-R/mice did not improve survival, with
a trend toward increased mortality (Fig. 1B) (P 0.079; n 16).
In a subsequent study, prolonged daily treatment with Serp-1
Chen et al.




arch 8, 2014 by W







FIG 1 Serp-1 prolongs survival in MHV68-infected IFN-R/ mice and in wild-type ebolavirus-infected BALB/c mice. (A) Treatment with Serp-1 (100
g/kg/day) for 10 days beginning immediately after MHV68 infection in IFN-R/ mice prolonged early survival (P 0.048) by approximately 10 days (n
60 mice). (B) Treatment with NSP given immediately after MHV68 infection for 10 days did not improve survival, with a trend toward increased mortality
compared to saline (P  0.079; n  12). (C) Treatment with Serp-1 for the first 30 days postinfection, beginning on the day of infection, further prolonged
survival in MHV68-infected IFN-R/mice compared to the saline-treated mice (P 0.02; n 10). (D) Treatment for 10 days with Serp-1 beginning 21 days
after MHV68 infection produced only a nonsignificant trend toward improved survival (P 0.326; n 12). (E) Treatment with Serp-1 for 30 days beginning 7
days postinfection again significantly improved survival (P 0.025; n 12). (F) Serp-1 treatment at 100 g/kg/day similarly improved survival in ebolavirus-
infected BALB/c mice but did not alter survival at lower doses (ANOVA, P 0.011) (Kaplan-Meier survival analysis).
Viral Serpin Improves Survival in Lethal Infections
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starting on the day of infection and continuing for the first 30 days
postinfection (100 g/kg i.p.) prolonged survival even further in
HV68-infected IFN-R/ mice, for up to 150 days (Fig. 1C)
(P  0.02; n  10). Of the 30-day-treated mice infected with
MHV68, all mice treated with Serp-1 were alive for up to 80 days,
and three of the five mice were alive for up to 150 days. In contrast,
four out of the five saline-treated mice were dead by 50 days.
Serp-1-treated mice with prolonged survival were euthanized at
150 days for a study analysis, although appearing healthy. Treat-
ment with Serp-1 starting at 3 weeks afterHV68 infection pro-
duced a nonsignificant trend toward improved survival (Fig. 1D)
(P 0.685; n 12). However, when Serp-1 treatment was begun
at 1 week postinfection, there was again a significantly improved
survival (Fig. 1E) (P 0.024; n 12), with survival for up to 150
days, at which time mice that remained healthy were euthanized.
On general inspection, mice treated with Serp-1 for 10 days dis-
played fewer signs of infection, with reduced lethargy and hunch-
ing, and with 30 days of Serp-1 treatment, the MHV68-infected
mice had ongoing freedom from signs of disease or sepsis.
Serp-1 reducedmortality in the ebolavirusmousemodel. In a
separate pilot study of ebolavirus infection performed in a BSL4
facility (HF, National Microbiology Laboratory, Public Health
agency, Winnipeg, Manitoba, Canada), in 24 BALB/c mice (6
mice/treatment group), treatment with Serp-1 at 5 to 100 g/kg
reduced tissue inflammation, necrosis, and necessity for euthana-
sia after virus infection (10 the LD50 of mouse-adapted Zaire
ebolavirus) (Fig. 1F) (P 0.011; n 24 mice) (see also Table S1 in
the supplemental material). Survival was increased from 6 to an
average of 10 to 14 days after treatment with Serp-1 at 100 g/kg
for 10 days (first dose i.v. prior to infection, followed by 9 days of
i.p. dosing). Serp-1 treatment at the lower doses did not prolong
survival or reduce tissue necrosis. The usual survival time is 6 to 7
days after ebolavirus infection, and based on predicted survival,
mice were euthanized at 14 days, irrespective of signs of infection.
There was 90 to 100% mortality rate in untreated animals.
Serp-1 treatment reduceddetectable infecting virus.MHV68
was detected in infiltrating mononuclear cells in the aortic adven-
titia (Fig. 2A), lung epithelium (Fig. 2C), and colon (Fig. 2E) on
immunostained tissue sections. Serp-1 treatment for 10 days be-
ginning immediately after HV68 infection reduced positive
staining for HV68 in the lungs (Fig. 2D) and colon (Fig. 2F)
compared to that for saline-treated mice (P  0.004 and 0.015,
respectively) (Fig. 2G). Serp-1 produced a nonsignificant trend
toward reduced aortic staining forHV68 (Fig. 2B and G) (P
0.168). RT-PCR analysis detected a nonsignificant (2.5- to 10-
fold) reduction in the HV68 genome after Serp-1 treatment
compared to saline (for HV DNA binding protein, 2.5-fold reduc-
tion [P  0.740]; for HV capsid, 10-fold reduction [P  0.250];
see RT-PCR data analysis in Fig. 7A). In vitro analysis of Serp-1
treatment on MHV68 proliferation in NIH 3T12 cells did not
detect a significant difference in viral titers (see Fig. S2 in the
supplemental material). RT-PCR detected a similar reduction in
FFU equivalents (ZEBOV GP) for ebolavirus-infected mice with
Serp-1 treatment at 100-g/kg doses (Fig. 2H) at 6 days postin-
fection, but not with lower doses. Only 1 or 2 of the ebolavirus-
infected mice were tested for FFU; thus, standard error (SE) can-
not be computed. The lower mortality rate in both lethal infections
correlated well with reduced detected virus (Fig. 2G and H).
Serp-1, but not NSP, reduces pulmonary consolidation and
hemorrhage and gastrointestinal dilation after HV68 infec-
tion. HV68-infected IFN-R/ mice were followed up at 10
days and at 5, 12, and 15 weeks. Sixteen out of 31 saline-treated
mice (51.2%) had pulmonary consolidation and hemorrhage.
Pulmonary hemorrhage and consolidation were significantly re-
duced by Serp-1 treatment, with only 3/29 mice displaying pul-
monary pathology (10.3%; P  0.01). The gastrointestinal (GI)
tract (esophagus to colon) had marked dilatation in 6 saline-
treated mice (19.3%), but there was no dilatation of the GI tract
with Serp-1 treatment (P  0.02) (data not shown). Pulmonary
and GI inflammation were associated with early mortality (Pear-
son’s R 0.739 and 0.668, respectively).
At 10 days of follow-up, saline-treated IFN-R/ mice had
marked aortic adventitial inflammatory cell invasion, with less
aggressive invasion in the media (Fig. 3A). The lungs (Fig. 3C) and











100 g5 g 50 g 100 g Start Length Follow-up
IFN-R/ MHV68 14 7 7 0 10 10
MHV68 23 12 23 0 10 35 (5 wks)
MHV68 8 4 4 0 10 84 (12 wks)
MHV68 16 8 8 0 10 105 (15 wks)
MHV68 12 6 6 21 10 140 (20 wks)
MHV68 10 5 5 0 30 140 (20 wks)
MHV68 12 6 6 7 30 140 (20 wks)
MHV68 14 7 7 0 10 10
MHV68 16 8 8 0 10 56 (8 wks)
BALB/c None 7 0 10 10
Ebolavirus 6 6 0 10 14
Ebolavirus 6 6 0 10 14
Ebolavirus 6 6 0 10 14
Ebolavirus 6 6 0 10 14
a Treatment start is the time when treatment was begun, day 0 is the day of viral infection, length of treatment is the duration of daily injections or treatments, and follow-up is the
planned follow-up times postinfection. “g” is used for “g/kg.”
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colon (Fig. 3E) also had marked inflammatory mononuclear cell
invasion. Serp-1 treatment significantly reduced inflammatory
cell invasion in the aortic adventitia (Fig. 3B and J) (P  0.010)
and lungs (Fig. 3D and J) (P  0.047) and demonstrated a trend
toward reduced inflammatory cell invasion in the GI tract (Fig. 3F
and J) (P  0.270). At 5, 12, and 15 weeks, there was a less pro-
nounced, ongoing trend toward reduced inflammation in aorta,
lung, and colon sections (not shown).
NSP treatment increased inflammatory cell invasion in
MHV68-infected mice compared to saline-treated mice. NSP-
treated mice had significantly increased cell invasion into the aor-
tic adventitia (Fig. 3G and K) (P  0.020), the lung interstitium
(Fig. 3H and K) (P 0.009), and the colon submucosa (Fig. 3I and
K) (P  0.018) compared to saline (Fig. 3A and C, E, and K,
respectively). There was, however, no GI dilatation seen in NSP-
treated mice.
Early CD11b macrophage invasion was significantly re-
duced with Serp-1 treatment after HV68 infection. Serp-1
treatment for 10 days reduced CD11b-positive cell counts in aorta
(Fig. 4A, D, and G) (P 0.048) and lung (Fig. 4B, E, and G; P
0.005) tissue sections fromHV68-infected mice at 10 days. No
significant differences in macrophage counts were detected in co-
lon with Serp-1 treatment (Fig. 4C, F, and G) (P  0.096). In
contrast, Serp-1 did not alter CD3
T cell counts in aorta (Fig. 4H,
FIG 2 Serp-1 treatment reduces detectable MHV68 antigen expression in IFN-R/ mice at 10 days’ follow-up and ZEBOV GP expression (FFU equivalents)
for ebolavirus in BALB/c mice at 14 days’ follow-up. Immunohistochemical staining for MHV68 at 10 days’ follow-up demonstrated positively stained
mononuclear cells (brown) in aortic (A), lung (C), and colon (E) histologic sections from saline-treated IFN-R/ mice. Positively stained cells were detected
predominantly in the aortic adventitial layer (A), in interstitial and bronchial epithelial layers in the lung (C), and in submucosa and serosa in the colon (E).
Positively stained cells (mean count per high-power field) were significantly reduced with Serp-1 treatment in lung (D and G) and colon (F and G) sections (P
0.004 and P 0.015, respectively; n 14), with only borderline reductions in aorta (B and G). Arrowheads indicate cells staining positively for MHV68. FFU
equivalents for ebolavirus were also reduced with Serp-1 treatment at 100-g/kg doses for 10 days but not with lower Serp-1 doses at 6 days’ follow-up (H) (n
31). SE cannot be calculated for the ebolavirus FFU measurements, as only 2 representative mice were tested. For MHV68-positive IHC-stained sections, the
magnification is400. Insets represent higher-power (1,000) magnification.
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J, and N) (P  0.197), lung (Fig. 4H) (P  0.172), or colon on
immunostained tissue sections (Fig. 4H) (P  0.197, P  0.172,
and P 0.490, respectively).
Serp-1 reduced necrosis and inflammation in the ebolavirus
mousemodel. Analysis of specimens clearly differentiated treated
and nontreated mice after ebolavirus infection. Saline control-
treated ebolavirus-infected mice demonstrated severe inflamma-
tory cell invasion with associated necrosis in the spleen (Fig. 5A)
and liver (Fig. 5C). These inflammatory and necrotic changes were
reduced at higher Serp-1 doses, with significantly reduced spleen
FIG 3 Large inflammatory cell infiltrates were found in the aortic adventitia (A) and lung (C) in saline control-treated MHV68-infected IFN-R/ mice at 10 days’
follow-up. Serp-1 treatment significantly reduced cell counts in aortic sections (A, B, and J) (P0.01;n14). Inflammatory cells infiltrates accompanied by hemorrhage
and alveolar consolidation are seen in lung sections from saline-treated MHV68-infected control mice (C). Infiltrating cells were reduced after Serp-1 treatment
(D and J) (P 0.047). Serp-1 treatment produced a nonsignificant reduction in inflammatory cells (F and J) (P 0.27) in colon sections compared to saline (E).
Inflammatory cell counts were increased in the aortic adventitia (G and K) (P 0.02), lung (H and K) (P 0.009), and colon (I and K) (P 0.018) in NSP-treated
MHV68-infected mice compared to saline controls. Bar graphs demonstrate numbers of invading cells per high-power field, three fields counted per section in
Serp-1-treated (J) and NSP-treated (K) MHV68-infected mice compared to saline controls (n 14). Arrowheads indicate the mononuclear cell infiltrates. Thick arrows
indicate lung hemorrhage. Cell count is indicated as mean per high-power field SE for H&E-stained sections. Magnification,400.
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lymphoid necrosis (Fig. 5B and E) (P  0.009 for 100 g/kg of
Serp-1) and marginal zone hyperplasia (Fig. 5F) (P  0.019 for 50
g/kg of Serp-1 and P 0.008 for 100g/kg of Serp-1). There was a
trend toward reduced intravascular macrophage counts (Fig. 5G)
(P  0.06 for 100 g/kg of Serp-1). Serp-1 treatment also reduced
hepatocyte necrosis at higher doses (Fig. 5D and H) (P 0.02).
Neuroserpin and Serp-1 produced opposing effects on im-
mune cell responses in spleen cell isolates. Effects on splenocyte
immune cell responses in MHV68-infected mice were assessed in
mice treated for 10 days with either Serp-1 or NSP. Splenocytes
isolated from one mouse did not provide sufficient counts for flow
cytometry analyses; therefore, splenocytes from the same experi-
mental group were pooled and analyzed. We would note that flow
analysis is generally considered a qualitative finding and not a
quantitative analysis, and we would thus consider these findings to
be more qualitative and indicative of trends in cell responses to
infection and treatment strategies. Serp-1 selectively increased
CD11c cells (macrophages and dendritic cells [DCs]) in the spleen
(Fig. 6A) (P  0.045) at 10 days. At 5 weeks’ follow-up, Serp-1
significantly reduced NK1.1 cells (P  0.030) and CD3 CD4 T
helper cells (P 0.046) but increased CD3 CD8 cytotoxic T cells
(P 0.001), suggesting a late restoration of sepsis-driven change
in immune cell responses (data not shown).
Conversely, NSP significantly reduced a broad spectrum of im-
mune cell responses in the spleen at 10 days (Fig. 6B). Specifically,
CD11c (macrophages and dendritic cells; P 0.010), CD4 IL-4 (T
helper 2 [Th2]; P 0.023), CD3 CD8 (Tc cells; P 0.002), CCR6
(nonactivated memory T cells and dendritic cells; P  0.030),
CD19 (B cells; P  0.008), CD83 (activated or mature dendritic
cells; P  0.010) and CD206 (macrophages and dendritic cells;
P  0.035) cells were reduced, indicating significant systemic ef-
fects of NSP on immune responses. NSP treatment could not be
FIG 4 Serp-1 inhibits invasion of CD11b
 but not CD3
 cells into the aorta and lungs in MHV68-infected IFN-R/ mice at 10 days’ follow-up (n  14).
Increased numbers of invading CD11b
 cells were found in the aortic adventitia (A), lung (B), and colon (C) in saline-treated control mice. Serp-1 treatment
significantly reduced CD11b-positive cell counts in the aorta (D and G) (P  0048) and lung (E and G) (P  0005) but not the colon (F and G) (P  0.098)
compared to saline controls. CD3
 cells were detected in the aortic adventitia, lung, and colon in saline-treated mice, with smaller numbers in the lung and with
nonsignificant decreases in Serp-1-treated mice (H) (P 0.197, 0.172, and 0.49, respectively) (n 14). Positively stained cells are indicated as mean count per
HPF SE. Arrows indicate CD11b
 cells. Magnification,400. Insets represent higher-power (1,000) magnification.
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assessed at 5 weeks in MHV68-infected mice due to the poor sur-
vival. These data suggest that NSP has potential to exacerbate im-
mune dysfunction in sepsis.
Serpin treatments altered serpin and cytokine gene expres-
sion. Serp-1 significantly increased aortic gene expression for the
regulatory thrombolytic serpins plasminogen activator inhibi-
tor-1 (PAI-1; P 0.020) and, unexpectedly, NSP (P 0.032; Fig.
7A) in MHV68-infected mouse aortic RNA isolates. The aorta
sections of Serp-1-treated mice also had significantly altered ex-
pression of inflammatory mediators found in DIC and sepsis, with
significant reduction in E selectin (P  0.048) (Fig. 7A) and in-
creased IL-10 (P  0.031) (Fig. 7A) and addressin (P  0.002)
(Fig. 7A). Compared to findings for saline-treated mice, NSP de-
creased gene expression of IL-17 and IL-10 (P 0.006 and 0.041,
respectively) (Fig. 7A) and increased PAI-2 (P 0.021) (Fig. 7A).
When comparing Serp-1 and NSP, Serp-1 was found to increase
FIG 5 Serp-1 reduced spleen and liver lesions in mouse-adapted Zaire ebolavirus infections in BALB/c mice. H&E-stained sections of spleen (A and B) and liver
(C and D) from ebolavirus-infected mice are shown. Control saline-treated sections demonstrate the severe lymphoid hyperplasia of the periarteriolar sheaths
(PAL), particularly the marginal zone (arrows) in the spleen (A) that obscures much of the red pulp (R) in infected mice. More normal splenic architecture is seen
in the Serp-1 (100 g/kg/day)-treated mice (B). Moderate to severe necrosis and accompanying inflammation in the periportal and midzonal hepatocytes
(arrows) with evidence for severe disruption of the lobular architecture and relative sparing of the central lobular hepatocytes in saline-treated mice can be seen.
There is widespread microvesicular lipid degeneration (arrows) and hepatocellular necrosis (arrowheads) disrupting the hepatic cords in control-treated mice
(C). Serp-1 markedly reduced evidence for necrosis and tissue damage in hepatic sections (D). P, portal; CV, central vein. Magnification, 100. Bar graphs
demonstrate a clear dose-dependent reduction in spleen lymphoid necrosis (E), marginal zone hyperplasia (F), vascular macrophage invasion (G), and
hepatocyte degeneration (H) with Serp-1 treatment at the higher doses. Histology was scored by J. Abbott, blinded to treatment, using a scale of 0 to 5, with
increasing severity at higher numbers (n 31); data represent mean scores SEs. Magnification,100.
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IL-10 (P 0.001) (Fig. 7A), basic fibroblast growth factor (bFGF)
(P 0.022) (Fig. 7A), addressin (P 0.001) (Fig. 7A), PAI-1 (P
0.021) (Fig. 7A), and NSP (P  0.009) (Fig. 7A), whereas NSP
reduced IL-6 (P  0.016) (Fig. 7A) and PAI-2 (P  0.016) (Fig.
7A). Serp-1 thus modulated gene expression for serpins that reg-
ulate coagulation as well as inflammatory adhesion molecules and
cytokines, with overall anti-inflammatory action, while NSP tar-
geted a different set of serpins and cytokines, some with proin-
flammatory activity. These findings suggest a rebalancing of coag-
ulation and thrombolytic cascades as well as inflammatory and
immune responses with Serp-1 treatment.
Serp-1 modified MHV68-induced changes in clotting re-
sponses and cytokines. Serp-1 treatment for 10 days significantly
increased IL-10 levels in circulating blood (P 0.032) compared
to those in the saline-treated controls at 10 days’ follow-up after
MHV68 infection (Fig. 7B) (34). In contrast, NSP significantly
reduced IL-10 levels (P  0.022; Fig. 7B) compared to those in
saline-treated controls.
MHV68-infected mice had prolonged bleeding times compared
to noninfected normal mice at 10 days after infection (P  0.016)
(Fig. 7C). Serp-1 and NSP treatment reduced bleeding times com-
pared to those obtained with saline treatment (P  0.046 and P 
FIG 6 Serp-1 and NSP had opposing effects on splenocyte responses assessed by flow cytometry. Serp-1 significantly increased CD11c counts at 10 days
postinfection (A) (P 0.045; n 14). Conversely, NSP reduced CD11c (macrophages and DCs; P 0.010), CD4 IL-4 (Th2 cells; P 0.023), CD3 CD8 (Tc cells;
P 0.002), CCR6 (nonactivated memory T cells and DCs; P 0.030), CD19 (B cells; P 0.008), CD83 (mature DCs; P 0.01), and CD206 (macrophages and
DCs; P 0.035) cells at 10 days (B) (n 14). Cell counts are presented as means SEs. *, **, and ***, P 0.05, P 0.01, and P 0.009, respectively.
Viral Serpin Improves Survival in Lethal Infections




arch 8, 2014 by W







0.011, respectively) (Fig. 7C), as predicted based upon reduced lung
hemorrhage. NSP reduced bleeding time more profoundly than did
Serp-1 (P 0.017) (Fig. 7C). Serp-1 treatment significantly reduced
fXa-positive cells in immunostained aortic sections (P 0.016) (Fig.
7D, E, and F) fromHV68-infected mice at 10 days.
Thus, Serp-1 treatment for 10 days in MHV68-infected mice
was capable of significantly modifying both coagulation re-
sponses, reducing bleeding, and anti-inflammatory responses,
with increased IL-10. The associated reduction in fXa and in-
creases in gene expression for anti-thrombolytic serpins together
with increased IL-10 are associated with a preserved immune cell
response, unlike NSP, suggesting that myxomaviral Serp-1 can
restore balance to the coagulation cascade and increase anti-in-
flammatory cytokine responses without significantly suppressing
overall immune cell activation.
DISCUSSION
We have examined the effect of treatment with a potent myxoma-
virus-derived anti-inflammatory purified serpin protein, Serp-1,
in an MHV68 model of lethal viral sepsis. Serp-1 improved sur-
vival while altering virus load, coagulation, hemorrhage, and in-
flammatory responses (26, 27). In contrast, a mammalian serpin,
neuroserpin, that targets only the thrombolytic serine proteases
and not the thrombotic proteases, was ineffective. A second lethal
FIG 7 Serp-1 and NSP yielded opposing changes on coagulation and inflammatory pathway gene expression and activity in MHV68-infected mouse aortas at 10 days
(n 14). Serp-1 increased gene expression for IL-10 (P 0.001), bFGF (P 0.022), addressin (P 0.001), PAI-1 (P 0.021), and NSP (P 0.009) and decreased IL-6
(P 0.016) and PAI-2 (A) (P 0.016), compared to NSP. On immunostained sections, Serp-1 (B) increased IL-10 levels (ELISA) in plasma samples from MHV68-
infected mice (P0.032), while NSP reduced IL-10 levels (F) (P0.022). Bleeding time was increased in MHV68-infected mice compared to noninfected mice (C) (P
0.016,n14). Serp-1 and NSP both decreased bleeding time compared to that in MHV68-infected saline controls (P0.046 andP0.011, respectively;n21). Serp-1
increased bleeding time compared to NSP (P 0.017). Serp-1 reduced fXa staining in aortic sections compared to control MHV68-infected mice (E and F) at 10 days
compared to saline controls (D and F) (P 0.016; n 6). All values are provided as means SEs; arrows indicate fXa staining. Magnification,400. Insets represent
higher-power (1,000) magnification. *, **, and ***, P 0.05, P 0.01, and P 0.009, respectively.
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infection, with mouse-adapted Zaire ebolavirus (4, 28, 29), was
also assessed, and in this mouse model, Serp-1 treatment again
reduced viral load necrosis and inflammation and improved sur-
vival.
Serp-1 improved survival when given starting on the day of
infection and remained effective when given starting at 7 days after
MHV infection but not when given 21 days after initial infection,
suggesting benefit both after incidental exposure and as a prophy-
laxis for early infections. The fact that Serp-1 improved survival in
infections with two unrelated viruses, a herpesvirus and a filovi-
rus, suggests potential for broad applicability in viral sepsis.
HV68 infection is lethal in IFN-R-deficient mice, which have
increased susceptibility to virus infection and in which host im-
mune response is unable to clear the infection. The mouse-
adapted Zaire ebolavirus strain is, however, lethal in wild-type
BALB/c mice, indicating that the antiviral efficacy displayed by
Serp-1 for MHV68 is not limited to IFN- receptor-deficient mice
or to either DNA or RNA virus infections. In order to examine the
mechanism of action of Serp-1, we have focused on the MHV68
infection model.
MHV68 infections in IFN-R-deficient mice and mouse-
adapted Zaire ebolavirus in wild-type BALB/c mice provide mod-
els for lethal infections with two separate viral families, represent-
ing both DNA and RNA viruses. These differing infections were
studied to determine the range of potential efficacy of viral immu-
nomodulating serpin treatments. MHV-68 is widely used as a
mouse model for Epstein Barr virus (EBV) and human herpesvi-
rus 8 infections (27–29, 35) and is a well-characterized rodent
model for studying gammaherpesviruses. MHV68 infection in
IFN-R-deficient mice provides an extension of this model, with a
marked inflammatory cell response and hemorrhage providing a
viral sepsis model.
The mouse ebolavirus model is used as an initial model system
for assessing the response of ebolavirus to serpin treatment; how-
ever, the mouse ebolavirus model is generally considered a model
that only partially reproduces ebolavirus infection seen in humans
and nonhuman primates (NHPs). Mouse-adapted ebolavirus in-
fections are lethal but are reported not to reproduce the coagu-
lopathy that is observed in humans and NHPs. Thus, future ex-
periments are planned in collaboration with researchers and
facilities capable of examining the efficacy of these serpins as ther-
apeutics in the more aggressive level 4 animal models that include
the coagulopathy syndrome. We would nevertheless reemphasize
that this initial observation using the mouse ebolavirus model
provides initial supportive evidence for efficacy in treating a range
of differing lethal viral infections that occur both in a knockout
model (IFN-R/) and in wild-type (BALB/c) mouse models.
Serp-1 targets both thrombotic (fX and fII) and thrombolytic
(tPA, uPA, and plasmin) proteases (12–15, 18) and was capable of
reducing tissue inflammation and hemorrhage in MHV68-in-
fected mice, whereas mammalian NSP, which targets only throm-
bolytic cascade proteases (tPA and uPA) (21, 23), was ineffective.
This suggests that Serp-1 alters viral sepsis and macrophage inva-
sion through inhibition of fX and/or fII or via combined effects on
both thrombotic and thrombolytic (tPA and uPA) pathways.
Among MHV68-infected mice, the majority that died had lung
consolidation and hemorrhage. Although lung hemorrhage is not
seen frequently in this mouse model, alterations in coagulation
pathway proteases are known to locally modify innate immunity
in affected tissues without overt hemorrhage or fibrin deposition.
The mechanism for reduction in pulmonary hemorrhage with
Serp-1 treatment in MHV68-infected mice logically may be di-
rectly related to inhibition of tPA and uPA. The reduced bleeding
time produced by Serp-1 may be the result of inhibition of fX and
fII by Serp-1, which may reduce excess coagulation and consump-
tion of clotting factors (consumptive coagulopathy), in septic
states. Serp-1 treatment may also result in a combined regulation
of both clot-forming and clot lysis pathways (2–10). Thus, Serp-1
may reestablish balance in coagulation pathways in lethal hemor-
rhagic viral infections. The partial reversal of the prolonged bleed-
ing time and the associated reduction in detectable fX in the aortas
of MHV68-infected mice suggest that Serp-1 targets both throm-
botic and thrombolytic pathways. PCR array analysis also detected
altered gene expression for proteases and serpins (nonsignificant
reductions in tPA and uPA and significant increases in fII, NSP,
and PAI-1), which may extend this activity. Prior studies with
antithrombin and drugs that inhibited only thrombosis or throm-
bolysis did not prove consistently beneficial (9, 10, 29). Treatment
with fX inhibitors in animal models has also indicated a modest
improvement in sepsis (35). Combined targeting of both throm-
bolytic proteases (tPA and uPA) as well as thrombotic proteases fX
and fII may enhance efficacy in treating viral sepsis.
Both cascades activate inflammatory cell responses: tPA and
uPA, via activation of matrix metalloproteinases and growth fac-
tors (14, 18, 36), and thrombin and fX, via activation of protease-
activated receptors (PARs) (2, 3, 7, 8), increasing inflammatory
cell invasion and activation.HV68 traffics into the lung by 10 to
12 days after injection, with acute infection of lung and persistent
infection in B lymphocytes, epithelial cells, and macrophages (26,
27). Serp-1 dramatically reduced numbers of cells staining posi-
tively for HV68 in the lungs and GI tract compared to saline
treatment (P  0.004 and P  0.015, respectively) and similarly
reduced FFU for ebolavirus in liver and blood samples from in-
fected mice. There was an associated significant reduction in in-
vading CD11b-positive macrophages in MHV68-infected mice
but no significant reduction in CD3-positive T cells, indicating
reduced acute inflammation. Serp-1 may decrease spread and
proliferation of unrelated viruses simply by blockade of macro-
phage or other inflammatory cell invasion (27), or this serpin may
represent a defense mechanism by which one virus protects its
territory from invasion by other pathogens, e.g., territorial de-
fenses (37). Changes in the microbiome population are known to
alter the species of infectious agents living in a host and have been
recently reported to alter systemic host immune responses (37,
38). Effects of unrelated viruses on proliferation of other, differing
viruses have also been reported previously (37). Serp-1 mediated
inhibition of proliferation of other unrelated viruses may thus
represent a natural viral defense against invading viruses, or this
serpin may simply target pathways central to generation of a septic
state.
Arterial inflammatory cell invasion may also be required for
virus spread, as blood vessels transport immune cells to infected
sites. The arterial wall also acts as a source for clotting factors. On
flow cytometry, Serp-1 did not reduce the majority of early cellu-
lar responses in spleens at 10 days postinfection, with the excep-
tion of an increase in CD11c-positive macrophages and/or den-
dritic cells. In contrast, NSP produced an early generalized
reduction in immune cell responses, with reductions in CD11c,





MHV68-infected mice. In aortic samples, Serp-1 significantly re-
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duced macrophage and increased IL-10 gene expression in
HV68-infected mice, with potential to reduce local aortic in-
flammation (38). The increased IL-10 in the sera of MHV68-in-
fected mice with Serp-1 treatment may correlate well with prior
studies indicating that IL-10 release suppresses macrophage and T
cell activation and may be protective in septic states (31–33). Ad-
ditionally, IL-10 has been reported to modify both thrombotic
and thrombolytic activity in sepsis (31, 39). The increase in aortic
addressin (VadCAM) (34) conversely would suggest a trend to-
ward increased macrophage activation or potentially a rebalanc-
ing of septic immune responses. Thus, Serp-1 may prevent local
inflammatory cell invasion and viral dissemination without in-
ducing systemic immune dysfunction, as evidenced in splenocyte
analysis. As an opposing response, NSP suppression of a wide
array of immune cells may exacerbate immune paralysis induced
during viral sepsis.
We postulate that the evolution of potent viral serpins over
millions of years has produced new and highly effective immune
modulating agents. Serp-1 represents a new class of antimicrobial
agent with potential for treatment in severe viral sepsis and DIC.
This activity extends the previously demonstrated anti-inflamma-
tory activity in animal models of vascular disease. Viral serpins
have previously demonstrated potential for treatment of other
systemic inflammation-based disorders, ranging from atheroscle-
rosis, arteritis, and arthritis to transplant rejection. Severe infec-
tious viral and bacterial infections that cause systemic cytokine
storm and coagulopathies (DIC) remain an unmet need associ-
ated with high mortality and few, if any, effective treatments. For
bacterial infections, antibiotic treatments are effective when given
early; however, treatment for viral infections remains limited to
selected number, and there is associated greater lethality in severe
systemic proinflammatory viral infections. With our work and
work by others, we propose that the administration of anti-in-
flammatory serpins targeting the coagulation and inflammatory
response systems has therapeutic potential for treatment of dis-
seminated viral sepsis and dysregulated coagulation and inflam-
mation. Serp-1 protein therapy has already been successfully
tested in a phase II clinical trial in patients with unstable angina
and coronary stent implant, with minimal side effects (24), indi-
cating potential for safe clinical application for systemic inflam-
matory disorders. In these coronary atherosclerosis patients, D-
dimer levels were reduced, indicating potential efficacy under
conditions that feature sepsis and DIC (14). We postulate that
Serp-1 treatment improves outcomes and survival in lethal viral
infections in mice through a dual rebalancing of both thrombotic
and thrombolytic cascades as well as promoting anti-inflamma-
tory cell responses through the upregulation of IL-10.
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